Ahmad, T and Ishaq, M and Eapen, M and Singh, Neeraj and Park, A and Karpiniec, S and Stringer, D and Fitton, H and Caruso, V and Eri, R, Fucoidan as an inhibitor of pro-inflammatory cytokines: potential candidate for treating inflammatory-related conditions, FASEB Journal, April 2-5 2022, Philidephia ISSN 1530-6860 (2022) [Conference Extract]
Material and methods:MTT cell viability assay was performed to assess the cytotoxicity of fucoidan extracts. Furthermore, a dose-response for fucoidan extracts was performed in LPS induced THP-1 cells and PBMCs after pre-treatment for 24 hours and levels of TNF-α, IL-1β, and IL-6 cytokines were measured using Enzyme-Linked Immunosorbent Assay (ELISA).
Results:MTT cell viability assay revealed that fucoidan extracts displayed no signs of cytotoxicity in THP-1 cells and PBMCs after incubation of 48 hours. Sandwich ELISA results exhibited that all fucoidan extracts reduced cytokine production in LPS stimulated PBMCs and human THP-1 cells in a dose-dependent fashion. Notably, the lower molecular fucoidan (5-30 kDa) extract from Macrocystis pyrifera was a highly effective inhibitor of pro-inflammatory cytokine at lower concentrations. Fucoidan extracts from all species demonstrated significant anti-inflammatory effects; however, the lower molecular weight extracts showed maximal effects at low concentrations. These observations on various fucoidan extracts offer insight into strategies that improve their efficacy against inflammation-related pathology.
Conclusion:We have successfully catalogued many fucoidan extracts based on their efficacy in LPS induced macrophages and PBMCs in down-regulating major pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6), potential targets in human inflammatory conditions. Further investigation would provide additional insights about the mechanism of action to test for therapeutic applications as an anti-inflammatory medication.
|Item Type:||Conference Extract|
|Keywords:||Fucoidan, Pro-Inflammatory cytokines|
|Research Division:||Biological Sciences|
|Research Group:||Industrial biotechnology|
|Research Field:||Bioprocessing, bioproduction and bioproducts|
|Objective Group:||Clinical health|
|Objective Field:||Treatment of human diseases and conditions|
|UTAS Author:||Ahmad, T (Mr Tauseef Ahmad)|
|UTAS Author:||Ishaq, M (Dr Muhammad Ishaq)|
|UTAS Author:||Eapen, M (Dr Mathew Eapen)|
|UTAS Author:||Singh, Neeraj (Mr Neeraj Singh)|
|UTAS Author:||Park, A (Dr Ah Young Park)|
|UTAS Author:||Karpiniec, S (Mr Samuel Karpiniec)|
|UTAS Author:||Stringer, D (Mr Damien Stringer)|
|UTAS Author:||Fitton, H (Dr Helen Fitton)|
|UTAS Author:||Caruso, V (Dr Vanni Caruso)|
|UTAS Author:||Eri, R (Associate Professor Raj Eri)|
Repository Staff Only: item control page